Research programme: somatropin oral - Access Pharmaceuticals

Drug Profile

Research programme: somatropin oral - Access Pharmaceuticals

Alternative Names: cobalamin-coated hGH-containing nanoparticles; CobOral™ hGH; CobOral™ somatropin

Latest Information Update: 16 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Access Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Growth disorders

Most Recent Events

  • 26 Mar 2014 No development reported - Preclinical for Growth disorders in USA (PO)
  • 30 Mar 2010 Access Pharmaceuticals and bioRASI enter into a collaborative clinical development agreement for oral formulations of injectable products
  • 20 Jan 2010 Preclinical trials in Growth disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top